An observational study in COVID-19, sponsored by Leiden University Medical Center. Completed at 51 sites in 10 countries. Per ClinicalTrials.gov, last updated 2023-03-01.
Sponsored by Leiden University Medical Center · Observational
Older and more vulnerable persons are more likely to get very ill when infected with the coronavirus, and have the highest COVID-19 morbidity and mortality rate. The majority of patients that are admitted to the hospital are older (>70 years), and some of them have been admitted to Intensive Care Units (ICU). In the case of rehabilitation of older patients post-COVID-19, we do not know what the course of recovery for these patients will be, and what treatment/approaches will deliver the best outcomes.
Persons that are recovering from a COVID-19 infection, and admitted on a geriatric ward for early rehabilitation, or geriatric rehabilitation ward or facility, can be included in the study. They will receive routine, usual care; participation in this study will not affect their rehabilitation care. Routine care data will be collected from their electronic patient files at admission to geriatric rehabilitation, and at discharge. This also includes some data about their premorbid status. In addition, study participants will be called six weeks and six months after discharge from rehabilitation and asked some questions about their recovery. There is no risk association with participation in this study. Data will be anonymously collected in an online database.
The primary aim of this study is to get insight into the course of recovery in (geriatric) rehabilitation patients affected by COVID-19 in Europe. Mainly, we are interested in functioning in activities of daily living (ADL-functioning) such as toileting, bathing, dressing, etc., and in quality of life. The second aim of this study is to get insight into the treatment modalities employed and the organization of geriatric rehabilitation that post-COVID patients in Europe receive. Therefore, we collect data on the types of care provided and the professionals involved. Moreover, we collect some patient characteristics such as year of birth, gender, date of admission and date of discharge; and data about complications such as delirium, pain, post-traumatic stress syndrome, hospital readmissions, and mortality. Our hypothesis is that most patients will show recovery during geriatric rehabilitation and in the six months after. However, we expect that the amount and/or speed of recovery will vary between patients.
INTRODUCTION AND RATIONALE The COVID-19 pandemic has hit the world hard, and older and vulnerable persons are more likely to get very ill when infected, and have the highest morbidity and mortality. The majority of patients that are admitted to the hospital are older (>70 years), and some of them have been, or are being, admitted to Intensive Care Units. Many patients stay on the ICU/hospital for weeks. To get back to the highest state of functional independence, these patients will need specialised care and treatment, therefore geriatric rehabilitation will be very likely required.
Geriatric Rehabilitation (GR) is defined as a multidimensional approach of diagnostic and therapeutic interventions, the purpose of which is to optimise functional capacity, promote activity and preserve functional reserve and social participation "in older people with disabling impairments." The goal of geriatric rehabilitation has been defined as "to assist [older people] to manage personal activities of daily living without the assistance of another person. If this is not possible, the goal is to minimize the need for external assistance through the use of adaptive techniques and equipment." Thereby focussing on the amelioration of dependency in activities of daily living. However, we are still in the dark about the amount of functional recovery of geriatric post-COVID-19 patients. We do know from the first lessons from Italy, that the rehabilitation process is difficult, and the course is capricious.
Before being able to assure the best outcomes for older post-COVID geriatric rehabilitation patients, we first have to be informed about what the clinical characteristics are, what treatment is provided, and what outcomes geriatric post-COVID-19 patients have in geriatric rehabilitation. Therefore, members of the Special Interest Group Geriatric Rehabilitation of the European Geriatric Medical Society (EuGMS) decided to conduct this multi-center observational cohort study into usual care data on the course of functional and clinical outcomes in post-COVID-19 geriatric rehabilitation patients in several European countries.
OBJECTIVES The primary objective of this study to get insight into the course of functional and medical recovery in (geriatric) rehabilitation patients affected by COVID-19 in Europe. The secondary objective is to get insight into the treatment modalities employed and the organisation of geriatric rehabilitation that post-COVID patients in Europe receive.
The study was conducted according to the principles of the Declaration of Helsinki (2013 version) and in accordance with the General Data Protection Regulation (GDPR) and in full conformity to any applicable state or local regulations in the participating countries.
RECRUITMENT In principle, patients admitted for geriatric rehabilitation due to COVID-19 morbidity will be informed by letter and asked if they have objections that their regular care data will be anonymously used for research purposes to improve practice in geriatric rehabilitation. If they do, the data will not be used (opt-out procedure). In some countries this will be conducted under the guidelines for service evaluation and audit, as it uses routine data, held entirely by the clinical care team. Where this is not possible because of local legislation or guidelines, informed consent will be obtained (opt-in procedure). During one-year (October 2020 - November 2021), patients were enrolled in the study.
Participants will receive standard rehabilitation treatment according to the discretion of clinical teams, which will likely be adapted to the specific needs of post-COVID-19 patients. This treatment includes physical therapy, occupational therapy, and medical treatment by an advanced nursing practitioner, geriatrician or medical specialist. This study will not influence any therapy provided or decisions about the medical treatment or treatment programs already used in the participating geriatric rehabilitation setting.
This study is observational and it is not anticipated that the observations will influence therapy or treatment, particularly since such indices, questionnaires and measurements are a regular part of the rehabilitation program.
STUDY MANAGEMENT For each participating geriatric rehabilitation facility in Europe one instructed local care professional will complete an online CASTOR database in which anonymous data from the clinical records of the included patients will be collected at admission, discharge and 6 weeks and 6 months follow-up. For countries with multiple participating sites, a country coordinator was appointed. Most country coordinators were the members of the Special Interest Group Geriatric Rehabilitation of the EuGMS.
DATA COLLECTION Variables collected
Data checks Data checks were performed during data collection to prepare for the steering board meetings that were held every two to three months with the country coordinators. In order to stimulate the achievement of the sample size, numbers of patients included were discussed during these meeting. Also structural missing or other remarkable things in the data were discussed during these meetings. Local care professionals were made aware of other missings or outliers in the data via email and asked to check and if possible complete or correct these data.
Sample Size calculation The primary outcomes are ADL functioning (Barthel index or derived from the USER or FIM) and quality of life (EQ-5D-5L). We performed a power calculation for a paired sample t-test on the primary outcome ADL-functioning (Barthel index). We assume a minimal clinically important difference of 2 points on the Barthel index as relevant, this is the mean difference between Barthel score at admission and Barthel score at discharge. The study would require a sample size of 52 (number of pairs) to achieve a power of 80% and a level of significance of 5% (two sided), for detecting a mean of the differences of 2 between pairs, assuming the standard deviation of the differences to be 5. We wanted to include a minimum of 52 patients per country which was agreed by the special interest group SIG EuGMS as being appropriate to generate the data we require. We aimed for a minimum of 250 participants in total.
STATSISTICAL ANALYSIS Different techniques will be used to analyze the data: Descriptive statistics will be used to give an overview of characteristics of the participants in the participating countries for all primary and secondary outcomes.
No imputation will be used for missing data; complete case analysis will be performed, under the assumption that the data is missing at random.
The level of significance will be set at p \< 0.05.
7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.
This study's enrollment of 723 is above the median of 268 across 3,208 observational studies indexed under COVID-19.
Browse COVID-19 studies →Leiden University Medical Center is the lead sponsor of 334 studies on the registry; 110 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will be recruited from geriatric rehabilitation settings in the participating European countries (Czech Republic, Germany, Ireland, Israel, Italy, Malta, the Netherlands, Russia, Spain, United Kingdom) and consists of patients rehabilitating after a COVID-19 infection in these countries. There were no selection criteria concerning health or demographic characteristics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients in European geriatric rehabilitation departments as the result of COVID-19 disease.
change in Activities of Daily Living (ADL)-functioning
The primary outcome measure is: ADL functioning. ADL functioning will be assessed with the Barthel Index (BI; scale 0-20 with 0 for complete dependence and 20 for optimal independence).
Time frame: Change in ADL-functioning from two weeks before admission to geriatric rehabilitation, until approximately 6 months after discharge from geriatric rehabilitation
change in Quality of Life (EQ-5D-5L)
Data about quality of life is collected using the 5-level EQ-5D (EQ-5D-5L; score of maximum 1 for best possible health state) \[8\].
Time frame: Change in quality of life from admission to geriatric rehabilitation until approximately 6 months after discharge from geriatric rehabilitation
length of stay in geriatric rehabilitation
difference between admission date and discharge date
Time frame: Date of discharge from geriatric rehabilitation minus data of admission to geriatric rehabilitation
discharge destination
cross-sectional outcome at the moment of discharge: destination of the patient at discharge from geriatric rehabilitation categorized as own home, assisted living, nursing home, hospital, deceased, or other.
Time frame: discharge destination is collected at discharge from geriatric rehabilitation (T2).
mortality
If the patient dies during geriatric rehabilitation or during follow-up until six months after discharge from the geriatric rehabilitation department, date of death is collected.
Time frame: date of death can be entered during geriatric rehabilitation (T2), at 6 weeks follow-up (T3), and at 6 months follow-up (T4).
complications during rehabilitation
cross-sectional outcome at the moment of discharge: if the patient experienced thromboembolism, delirium, pressure ulcer, or other complications during geriatric rehabilitation, this is recorded. (yes/no)
Time frame: complications that occured between admission and discharge from geriatric rehabilitation.
post traumatic stress disorder (PTSD)
During the follow-up telephonic interviews, the patient is asked if he/she has developed PTSD (yes/no)
Time frame: PTSS is collected collected at 6 weeks follow-up (T3), and at 6 months follow-up (T4).
Plan to share: Yes — Researchers who wish to conduct additional analyses, for example country-specific analyses, can apply for EU-COGER research data by sending an application to P.I. prof. Wilco Achterberg (W.P.Achterberg@lumc.nl). A standardized application form is available. Applications will be judged based on the originality of the research question and the feasibility of the analysis plan. When the application is approved, a data transfer agreement (DTA) will be signed to ensure that the receiving party will adhere to our co-authorship policy and will not share the data with third parties (and will store the data in line with the General Data Protection Regulation (GDPR), in case of non-EU member states). After the DTA has been signed, the research data will be shared in line with the GDPR and permission provided in the informed consent forms. We will use multi-factor authentication to ensure that no unintended persons will be able to access the data transfer.
Supporting information: Study protocol
Time frame: Data is currently available on request (see plan description)
Access criteria: see Plan Description
No publications or documents are linked to this record.
Ran from Oct 2020 to primary completion in Jul 2022, 21 months.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 21 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leiden University Medical Center →